Menopause Age and Anxiety-Depression

NCT07295093 | Completed

• 1 other identifier: TABED 1-25-1981
• Study Type: observational
• Target: 136
• Locations: 1 country
• Sites: 1

Brief Summary

Menopause is defined as the permanent cessation of menstrual cycles due to ovarian follicle depletion, typically occurring after age 50, and is associated with decreased estrogen levels. Primary ovarian insufficiency (POI) involves early ovarian dysfunction before age 40, with infertility as a key concern. Both menopause and POI may contribute to psychological symptoms, including anxiety and depression, influenced by sociodemographic and health factors. While literature reports anxiety in middle-aged women, data on its association with menopausal timing are limited. This study aims to compare women with POI and those undergoing natural menopause after age 40, assessing the relationship between age at menopause, anxiety, and depression, as well as the impact of fertility expectations on psychological well-being in POI patients.

Conditions

Menopause; Primary Ovarian Insufficiency (Poi); Anxiety; Depression; Menopausal Depression

Keywords

Menopause; Primary Ovarian Insufficiency (Poi); Anxiety; depression

Outcome Measures

Primary Outcomes (2)

• Beck Anxıety Inventory (BAI), Anxiety level

  Anxiety severity measured by the Beck Anxiety Inventory (BAI) during routine clinic visit.

  Baseline (single assessment at enrollment during routine clinic visit).

• State-Trait Anxiety Scale (STAI) 1-2, Anxiety level

  Anxiety severity measured by the State-Trait Anxiety Inventory (STAI) forms 1 and 2 during routine clinic visit.

  Baseline (single assessment at enrollment during routine clinic visit).

Study Arms (2)

Menopause group

Patients over 40 years of age who have undergone menopause and who visited our hospital's obstetrics and gynecology outpatient clinic for routine check-ups, without any additional diseases or complaints.

Other: Beck Anxıety Inventory (BAI); Other: State-Trait Anxiety Scale (STAI) 1-2

Primary ovarian insufficiency (POI) group

Patients who experienced menopause before the age of 40 and who visited our hospital's obstetrics and gynecology outpatient clinic for routine check-ups, without any additional diseases or complaints.

Other: Beck Anxıety Inventory (BAI); Other: State-Trait Anxiety Scale (STAI) 1-2

Interventions

Beck Anxıety Inventory (BAI) OTHER

Beck Anxıety Inventory (BAI) Description: The scale will be self-administered and completed by the patient during the routine outpatient clinic visit.

Also known as: State-Trait Anxiety Scale (STAI) 1-2

Menopause group; Primary ovarian insufficiency (POI) group

State-Trait Anxiety Scale (STAI) 1-2 OTHER

State-Trait Anxiety Scale (STAI) 1-2 Description: The scale will be self-administered and completed by the patient during the routine outpatient clinic visit.

Menopause group; Primary ovarian insufficiency (POI) group

Eligibility Criteria

• Age: 24 Years+
• Gender Eligibility Details: Eligible: Female participants only. This study specifically includes women who have undergone menopause, as well as women diagnosed with primary ovarian insufficiency (POI). Not Eligible: Male participants and individuals who do not identify as female.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A total of 136 participants were included in the study, of whom 83 were in the menopause group and 53 in the primary ovarian insufficiency group.

You may qualify if:

• Healthy women over 24 years of age who visited our hospital for routine outpatient check-ups, had been diagnosed with menopause, and had no history of psychiatric disorders before menopause.

You may not qualify if:

• Cardiovascular diseases including hypertension
• Type 1 or type 2 diabetes mellitus
• Morbid obesity
• Primary adrenal insufficiency
• Uterine fibroids
• Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease
• Hepatic dysfunctions
• Renal insufficiency
• Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9
• Neurologic diseases
• Psychiatric disorders
• Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever
• History of any malignancy
• History of exposure to chemotherapeutic agents or radiotherapy
• Individuals with a history of chronic or regular medication use that could cause anxiety or depression symptoms

Sponsors & Collaborators

• Ankara City Hospital Bilkent: lead

Study Sites (1)

Ankara Bilkent City Hospital

Ankara, Not Valid, 06100, Turkey (Türkiye)

Location

Related Publications (5)

• Bromberger JT, Meyer PM, Kravitz HM, Sommer B, Cordal A, Powell L, Ganz PA, Sutton-Tyrrell K. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health. 2001 Sep;91(9):1435-42. doi: 10.2105/ajph.91.9.1435.

  PMID: 11527777 BACKGROUND

• Zollner YF, Acquadro C, Schaefer M. Literature review of instruments to assess health-related quality of life during and after menopause. Qual Life Res. 2005 Mar;14(2):309-27. doi: 10.1007/s11136-004-0688-z.

  PMID: 15892422 BACKGROUND

• Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S467-72. doi: 10.1002/acr.20561. No abstract available.

  PMID: 22588767 BACKGROUND

• Bryant C, Judd FK, Hickey M. Anxiety during the menopausal transition: a systematic review. J Affect Disord. 2012 Jul;139(2):141-8. doi: 10.1016/j.jad.2011.06.055. Epub 2011 Jul 23.

  PMID: 21783260 BACKGROUND

• Grigolon RB, Ceolin G, Deng Y, Bambokian A, Koning E, Fabe J, Lima M, Gerchman F, Soares CN, Brietzke E, Gomes FA. Effects of nutritional interventions on the severity of depressive and anxiety symptoms of women in the menopausal transition and menopause: a systematic review, meta-analysis, and meta-regression. Menopause. 2023 Jan 1;30(1):95-107. doi: 10.1097/GME.0000000000002098. Epub 2022 Nov 7.

  PMID: 36576445 BACKGROUND

MeSH Terms

Conditions

Primary Ovarian Insufficiency; Anxiety Disorders; Depression

Condition Hierarchy (Ancestors)

Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases; Mental Disorders; Behavioral Symptoms; Behavior

Study Officials

• Merve Didem Eşkin Tanrıverdi

  Ankara City Hospital Bilkent

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Doctor

Study Record Dates

• First Submitted: December 4, 2025
• First Posted: December 19, 2025
• Study Start: December 15, 2024
• Primary Completion: August 5, 2025
• Study Completion: September 15, 2025
• Last Updated: December 19, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)